One of the trials is double-blinded - how would the patient know if he/she received vismodegib? And none of the trials are testing vismodegib as a single agent. Gemcitabine may not be revolutionary, but it does have established efficacy in pancreatic cancer. A complete response would not simply occur by "chance" - you'd expect to see at least one or two if the trial is enrolling several patients.
I don't know if the hedgehog inhibitors will or will not work, but I don't think making a judgement based on testimonials will necessarily give you any more clarity in this case.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.